Your fact-checks will appear here
The potential for Neuralink and other neurotech companies to treat dementia and other neurological disorders through device-based solutions by 2026.
Elon Musk is not marketing or clinically producing a “cognitive decline medicine” in the conventional pharmaceutical sense; his high-profile activity in the field centers on Neuralink, a brain‑compute...
There is no published human-trial evidence that improves cognitive function in dementia patients; Neuralink’s early human work has so far centered on demonstrating device implantation and neural signa...
Neuralink’s clinical trial program is built around an implantable intracortical device (the N1 implant and surgical R1 robot) tested in the PRIME first‑in‑human study and expanding into multiple indic...